Date: May. 19 th , 2023	
Your Name: Yi Xie	
Manuscript Title: Anti-ferroptotic PRKAA2 serves as a potential diagnostic and prognostic marker f	<u>or</u>
hepatoblastoma	
Manuscript number (if known): JGO-23-110-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time infilt for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May. 19	9 th , 2023		
Your Na	me:	Zhongqi Cui		
Manusci	ript Title:	Anti-ferroptoti	PRKAA2 serves as a potential diagnostic and prognostic	marker for
hepatob	lastoma			
Manusci	ript numb	er (if known):	JGO-23-110-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time infilt for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May. 19 th , 2023
Your Name	e: Sijia Fang
Manuscrip	t Title: Anti-ferroptotic PRKAA2 serves as a potential diagnostic and prognostic marker for
hepatoblas	stoma
Manuscrip	t number (if known): JGO-23-110-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame. Since the lintial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			

Please place an "X" next to the following statement to indicate your agreement:

Date: May. 19th, 2023	
Your Name: Guoging Zhu	
Manuscript Title: Anti-ferroptotic	PRKAA2 serves as a potential diagnostic and prognostic marker for
hepatoblastoma	
Manuscript number (if known):	IGO-23-110-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time infilt for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
	None.		
L			

Please place an "X" next to the following statement to indicate your agreement:

Date: May. 19 th , 2023	
Your Name: Ni Zhen	
Manuscript Title: Anti-ferroptotic PRKAA2 serves as a potential diagnostic an	prognostic marker for
hepatoblastoma	
Manuscript number (if known): JGO-23-110-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame. Since the lintial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
	illialiciai liiterests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
None.			
L			

Please place an "X" next to the following statement to indicate your agreement:

Date: _	May. 19) th , 2023		
Your Na	ame:	Jiabei Zhu		
Manus	cript Title:	Anti-ferroptoti	c PRKAA2 serves as a potential diagnostic and prognostic	marker for
<u>hepato</u>	blastoma			
Manus	cript numb	er (if known):	JGO-23-110-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time infilt for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
	and an age and age are		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
	illialiciai liiterests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
None.			
L			

Please place an "X" next to the following statement to indicate your agreement:

Date:	May. 19	th , 2023		
Your Nar	ne:	Siwei Mao		
Manuscr	ipt Title:	Anti-ferroptotic PRKAA2 serve	es as a potential diagnostic and prognostic	marker for
hepatobl	lastoma			
Manuscr	int numb	er (if known): JGO-23-110-C	1	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time infilt for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
	and an age and age are		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
	illialiciai liiterests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
None.			
L			

Please place an "X" next to the following statement to indicate your agreement:

Date: M	lay. 19 th , 2023
Your Name:	Fenyong Sun
Manuscript	Title: Anti-ferroptotic PRKAA2 serves as a potential diagnostic and prognostic marker for
hepatoblast	coma
Manuscript	number (if known): JGO-23-110-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
О	testimony	xnone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
	and an age and age are		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
42		V N	
12	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other		
	services		
12		V Nove	
13	Other financial or non- financial interests	XNone	
	illialiciai liiterests		
Ple	ease summarize the above o	onflict of interest in the fo	ollowing box:
_			
None.			
L			

Please place an "X" next to the following statement to indicate your agreement:

Date: May. 19 th , 2023	
Your Name: Qiuhui Pan	
Manuscript Title: Anti-ferroptotic PRKAA2 serves as a potential diagnostic and prognostic marker for	
hepatoblastoma	
Manuscript number (if known): JGO-23-110-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone			
	medical writing, article				
	processing charges, etc.) No time limit for this item.				
	No time limit for this item.				
	Time frame: past 36 months				
2	Grants or contracts from	XNone			
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
ь	testimony	xnone		
7	Support for attending	XNone		
,	meetings and/or travel			
	and an age and age are			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
42		V N		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None		
	services			
12		V Nove		
13	Other financial or non- financial interests	XNone		
Please summarize the above conflict of interest in the following box:				
_				
	None.			
L				

Please place an "X" next to the following statement to indicate your agreement:

Date:	May. 19 ^t	th , 2023					
Your I	Name:	Ji Ma					
Manu	script Title: /	Anti-ferroptoti	c PRKAA2 serves a	as a potential	diagnostic and p	prognostic i	marker for
<u>hepat</u>	oblastoma						
Manu	script number	er (if known):	IGO-23-110-CI				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone			
	medical writing, article				
	processing charges, etc.) No time limit for this item.				
	No time limit for this item.				
	Time frame: past 36 months				
2	Grants or contracts from	XNone			
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
ь	testimony	xnone		
7	Support for attending	XNone		
,	meetings and/or travel			
	and an age and age are			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
42		V N		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None		
	services			
12		V Nove		
13	Other financial or non- financial interests	XNone		
Please summarize the above conflict of interest in the following box:				
_				
	None.			
L				

Please place an "X" next to the following statement to indicate your agreement: